Skip to main contentAI and Advanced
/
ALKEM · NSEMarket ticker unavailable · configure an authorised index feed
AL
NSE · Equity shares · Biotechnology & Drugs14.00 · 0.27%
Alkem Laboratories ALKEM
NSE:INR 5,175
BSE:INR 5,609
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for ALKEM
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 5,161
Day rangeINR 5,148 — INR 5,265.5
52-week rangeINR 5,051 — INR 5,933.5
Volume3.04 L
Market cap66,990.07
P/E27.52
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)14,712.27
Net Income (INR Cr)2,301.8
Rev Growth (5 Year %)10.66
EPS Growth (5 Year %)7.75
P/E Ratio27.52
Book Value1,078.56
EPS204.6
Price/BV4.80Computed
Research path: Interpret Alkem Laboratories's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ALKEMAlkem Laboratories1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 20,872.97 | 17,691.1 | 15,574.9 |
| Accumulated Depreciation Total | -1,938.68 | -1,670.39 | -1,499.93 |
| Cash Equivalents | 77.29 | 107.35 | 0 |
| Other Liabilities Total | 856.99 | 712.18 | 636.69 |
| Accrued Expenses | 405 | 400.25 | 723.73 |
| Long Term Debt | 492.45 | 310.91 | 40 |
| Common Stock Total | 23.91 | 23.91 | 23.91 |
| Other Equity Total | 370.83 | 188.44 | 167.7 |
| Other Current Assets Total | 844.1 | 877.86 | 711.84 |
| Prepaid Expenses | 80.02 | 59.53 | 49.91 |
| Total Assets | 20,872.97 | 17,691.1 | 15,574.9 |
| Current Portof LT Debt/Capital Leases | 92.68 | 67.68 | 15.18 |
| Cash | 170.62 | 196.79 | 455.07 |
| Total Equity | 13,820.1 | 11,984.87 | 10,312.06 |
| Long Term Investments | 2,291.95 | 1,298.83 | 405.13 |
| Retained Earnings(Accumulated Deficit) | 13,389.82 | 11,736.37 | 10,100.91 |
| Total Common Shares Outstanding | 11.96 | 11.96 | 11.96 |
| Property/Plant/Equipment Total-Gross | 5,167.21 | 4,533.12 | 4,056.97 |
| Tangible Book Valueper Share Common Eq | 1,078.56 | 957.4 | 822.79 |
| Goodwill Net | 523.64 | 423.11 | 416.74 |
| Total Liabilities | 7,052.87 | 5,706.23 | 5,262.84 |
| Total Debt | 2,047.16 | 1,380.9 | 1,418.41 |
| Short Term Investments | 3,813.54 | 3,473.78 | 3,347.25 |
| Cashand Short Term Investments | 4,061.45 | 3,777.92 | 3,802.32 |
| Total Receivables Net | 3,775.96 | 3,177.44 | 3,064.12 |
| Notes Payable/Short Term Debt | 1,085.25 | 734.89 | 1,173.97 |
| Deferred Income Tax | 15.12 | 0 | Not available |
| Accounts Receivable-Trade Net | 3,004.88 | 2,507.63 | 2,285.46 |
| Property/Plant/Equipment Total-Net | 3,228.54 | 2,862.7 | 2,557.03 |
| Minority Interest | 528.83 | 448.76 | 402.34 |
| Total Current Liabilities | 4,782.7 | 3,966.96 | 3,994.55 |
| Total Inventory | 3,448.99 | 3,053.07 | 2,783.39 |
| ESOP Debt Guarantee | 35.54 | 36.15 | 19.54 |
| Accounts Payable | 2,244.18 | 1,937.35 | 1,748.12 |
| Other Currentliabilities Total | 955.59 | 826.79 | 333.55 |
| Total Long Term Debt | 869.23 | 578.33 | 229.26 |
| Intangibles Net | 400.64 | 114.57 | 57.58 |
| Other Long Term Assets Total | 1,878.1 | 1,781.79 | 1,529.58 |
| Note Receivable-Long Term | 339.58 | 264.28 | 197.26 |
| Total Current Assets | 12,210.52 | 10,945.82 | 10,411.58 |
| Capital Lease Obligations | 376.78 | 267.42 | 189.26 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.9
Price to Sale Ratio4.55
Growth
Debt 5Yr CAGR %2.7
Margins
Operating Margin 12m16.64
Operating Margin 5y Avg15.55
Net Profit Margin 12m15.98
Net Profit Margin 5y14.49
Yield
Dividend Yield %0.93
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk26.45
Analyst consensus
ConsensusBuy
Consensus score2.50
Analyst opinions18
Strong Sell count1
Sell count2
Hold count6
Buy count5
Strong Buy count4
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 49.70%
- FII
- 10.42%
- MF
- 16.71%
- Other
- 23.17%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Alkem completes acquisition of majority stake in Switzerland's Occlutech - Indian Pharma PostMarket news · 20 Jul 2026, 8:32 am
Alkem completes acquisition of majority stake in Switzerland's Occlutech Indian Pharma Post
Alkem Laboratories acquires Alkem Medtech shares for ₹1,100 crore - scanx.tradeMarket news · 17 Jul 2026, 4:13 pm
Alkem Laboratories acquires Alkem Medtech shares for ₹1,100 crore scanx.trade
Alkem Laboratories to hold EGM on Aug 17 for amalgamation with Adroit Biomed - scanx.tradeMarket news · 15 Jul 2026, 4:21 pm
Alkem Laboratories to hold EGM on Aug 17 for amalgamation with Adroit Biomed scanx.trade
Alkem Laboratories Ltd Technical Momentum Shifts Amid Mixed Indicator Signals - MarketsMojoMarket news · 15 Jul 2026, 8:04 am
Alkem Laboratories Ltd Technical Momentum Shifts Amid Mixed Indicator Signals MarketsMojo
Alkem Labs appoints Shivaditya Banerjee as Senior Vice President – Human Resources - Indian Pharma PostMarket news · 14 Jul 2026, 9:50 am
Alkem Labs appoints Shivaditya Banerjee as Senior Vice President – Human Resources Indian Pharma Post
Alkem Laboratories Downgraded to Sell Amid Mixed Financial and Technical Signals - MarketsMojoMarket news · 14 Jul 2026, 9:15 am
Alkem Laboratories Downgraded to Sell Amid Mixed Financial and Technical Signals MarketsMojo
Corporate actions
Events
- annual General MeetingAGM
- annual General MeetingCOM
- board MeetingsQuarterly Results
- dividendRs.10.0000 per share(500%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- dividendRs.43.0000 per share(2150%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Alkem Laboratories
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ALKEM
- BSE Code
- 539523
Questions
Stock FAQ
What is the symbol and ISIN of Alkem Laboratories?
Alkem Laboratories has the symbol ALKEM and ISIN - INE540L01014.
What is the current price of Alkem Laboratories?
Alkem Laboratories is currently trading at INR 5,175.00.
What are the year high and year low of Alkem Laboratories?
Alkem Laboratories has a year high of INR 5,933.50 and a year low of INR 5,051.00.
What is the market capitalization of Alkem Laboratories?
Alkem Laboratories has a market capitalization of INR 66,990.07 crore.
What is the P/E ratio of Alkem Laboratories?
Alkem Laboratories has a P/E ratio of 27.52.
What is the dividend yield of Alkem Laboratories?
Alkem Laboratories has a dividend yield of 0.93%.
How is the financial performance of Alkem Laboratories based on revenue, net income, and EPS?
Alkem Laboratories has revenue of INR 14,712.27 crore, net income of INR 2,301.80 crore, and EPS of INR 201.98.
What is the book value of Alkem Laboratories?
Alkem Laboratories has a book value of INR 1,078.56.
What is the debt-to-equity ratio of Alkem Laboratories?
Alkem Laboratories has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Alkem Laboratories?
Alkem Laboratories has a price-to-book ratio of 4.80 and a price-to-sales ratio of 4.55.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.